Cell to Cure

Cell to Cure is a Danish clinical-stage biotechnology company specializing in the development of allogeneic stem cell therapies derived from adipose tissue. A spin-out from the Cardiology Stem Cell Centre at Rigshospitalet, Copenhagen University Hospital, the company utilizes a proprietary manufacturing process to produce off-the-shelf mesenchymal stromal cell (ASC) products. These therapies are designed to treat a variety of conditions characterized by inflammation, immune dysregulation, and tissue scarring. Its current clinical pipeline includes advanced programs for autism spectrum disorder, non-ischemic heart failure, and radiation-induced hyposalivation, many of which are being developed in collaboration with leading academic and clinical partners.